title: Neurotoxicity of biologically targeted agents in pediatric cancer trials.
abstract: Biologically targeted agents offer the promise of delivering specific anticancer effects while limiting damage to healthy tissue, including the central and peripheral nervous systems. During the past 5-10 years, these agents were examined in preclinical and adult clinical trials, and are used with increasing frequency in children with cancer. This review evaluates current knowledge about neurotoxicity from biologically targeted anticancer agents, particularly those in pediatric clinical trials. For each drug, neurotoxicity data are reviewed in adult (particularly studies of brain tumors) and pediatric studies when available. Overall, these agents are well tolerated, with few serious neurotoxic effects. Data from younger patients are limited, and more neurotoxicity may occur in the pediatric population because these agents target pathways that control not only tumorigenesis but also neural maturation. Further investigation is needed into long-term neurologic effects, particularly in children.
authors.affiliation: Brain Tumor Institute, Children's National Medical Center, Washington, DC, USA.
authors.forename: Elizabeth M
authors.initials: EM
authors.lastname: Wells
authors.forename: Amulya A
authors.initials: AA
authors.lastname: Nageswara Rao
authors.forename: Joseph
authors.initials: J
authors.lastname: Scafidi
authors.forename: Roger J
authors.initials: RJ
authors.lastname: Packer
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001688:Biological Products / Q000009:adverse effects*; D006801:Humans; D009423:Nervous System Neoplasms / Q000188:drug therapy*; D020258:Neurotoxicity Syndromes / Q000209:etiology*; D010372:Pediatrics
chemical_list: D000970:Antineoplastic Agents; D001688:Biological Products